- Cellipont Bioservices has completed a new ballroom-style cleanroom equipped with a 50-litre single-use bioreactor.
- The expansion increases capacity for cGMP manufacturing of exosome, iPSC and MSC therapies.
Cellipont Bioservices has completed its ballroom-style cleanroom, which includes a 50-litre single-use bioreactor to support advanced cell therapy manufacturing. The expansion is part of the company’s investment strategy to meet demand for exosome, induced pluripotent stem cell and mesenchymal stem cell therapies.
The new bioreactor increases Cellipont’s cGMP capacity and is designed to enable clients to progress from early development to commercial-scale production. The system is intended to improve batch consistency, process scalability and production efficiency for allogeneic therapies. The upgrade also supports the company’s CDMO and contract manufacturing services.
According to the company, the facility strengthens the route from clinical development to commercialisation by offering scalability and streamlined scale-up processes. The equipment is positioned to help innovators reduce complexity during development and prepare products for regulatory expectations.
“Our newest cleanroom and 50-liter single-use bioreactor represent a significant milestone in our commitment to supporting the next generation of cell therapies.” He said the investment aims to help clients achieve consistency, throughput and regulatory compliance.
Darren Head, CEO of Cellipont Bioservices
Cellipont stated that its focus is on providing manufacturing capabilities that can support the commercial potential of allogeneic cell therapies and help advance treatments towards patients.
